FDA Clears Sandoz Biosimilar Of Amgen's Enbrel
The U.S. Food and Drug Administration on Tuesday approved Sandoz Inc.'s biosimilar for Amgen Inc.'s immunosuppressant Enbrel to treat certain types of arthritis and psoriasis, bringing the number of biosimilars the...To view the full article, register now.
Already a subscriber? Click here to view full article